SML0327
AM630
≥90% (HPLC), CP 55,940 antagonist, powder
別名:
6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, AM 630, Iodopravadoline
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C23H25IN2O3
CAS番号:
分子量:
504.36
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
製品名
AM630, ≥90% (HPLC)
SMILES string
COc1ccc(cc1)C(=O)c2c(C)n(CCN3CCOCC3)c4cc(I)ccc24
InChI
1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3
InChI key
JHOTYHDSLIUKCJ-UHFFFAOYSA-N
assay
≥90% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: >5 mg/mL
storage temp.
2-8°C
Quality Level
関連するカテゴリー
Application
AM630 has been used:
- as a cannabinoid 2(CB2) inhibitor to study the analgesic effect exerted by polysaccharopeptide from Trametes versicolor (TPSP).
- as a CB2 antagonist along with β-caryophyllene (BCP) to study its effects on re-epithilialization of fibroblast cells.
- as a CB2 antagonist to study its interaction with 17-β-estradiol in primary human osteoblasts.
Biochem/physiol Actions
AM630 is a selective CB2 cannabinoid antagonist/inverse agonist (Ki = 31.2 nM) with > 150-fold selectivity over CB1 receptors.
AM630 is a selective CB2 cannabinoid antagonist/inverse agonist.
AM630 is an aminoalkylindole and acts as a competitive antagonist of CP 55,940 and WIN 55,212-2. It also behaves as a competitive antagonist of anandamide and (R)-(+)-arachidonyl-1′-hydroxy-2′-propylamide (AM356).
Features and Benefits
This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Substances Subject to be Indicated Names
ishl_indicated
Substances Subject to be Notified Names
ishl_notified
SML0327-25MG:4548174001912 + SML0327-5MG:4548174001929 + SML0327-VAR: + SML0327-BULK:
jan
K A Jenkin et al.
British journal of pharmacology, 173(7), 1128-1142 (2014-12-30)
In diabetic nephropathy agonism of CB2 receptors reduces albuminuria and podocyte loss; however, the role of CB2 receptors in obesity-related nephropathy is unknown. The aim of this study was to determine the role of CB2 receptors in a model of
R Pertwee et al.
Life sciences, 56(23-24), 1949-1955 (1995-01-01)
AM630 (iodopravadoline), a novel aminoalkylindole, has been found to attenuate the ability of a number of cannabinoids to inhibit electrically-evoked twitches of the mouse isolated vas deferens. It did not block the inhibitory effects of morphine or clonidine on the
Marko Hojnik et al.
Biomedical reports, 3(4), 554-558 (2015-07-15)
The bone remodeling process is influenced by various factors, including estrogens and transmitters of the endocannabinoid system. In osteoblasts, cannabinoid receptors 2 (CB-2) are expressed at a much higher level compared to CB-1 receptors. Previous studies have shown that estrogens
Sachiko Koyama et al.
PloS one, 14(12), e0216104-e0216104 (2019-12-17)
Beta-caryophyllene is an odoriferous bicyclic sesquiterpene found in various herbs and spices. Recently, it was found that beta-caryophyllene is a ligand of the cannabinoid receptor 2 (CB2). Activation of CB2 will decrease pain, a major signal for inflammatory responses. We
Massimo Nabissi et al.
Oncotarget, 7(47), 77543-77557 (2016-10-22)
Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma (MM), both alone and in synergy with the proteasome inhibitor
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）